MPTP: a pharmacological tool to study parkinsonism.

MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is reported to selectively degenerate dopaminergic cells of the zona compacta of the substantia nigra and produce Parkinson's-like symptoms in man and animals. Although the exact mechanism of its neurotoxicity is not well defined, a major metabolite MPP+ may be responsible for the ultimate neuron toxicity. Several classes of drugs useful in Parkinson's disease are effective in reversing MPTP-induced neurotoxicity. Future pharmacological studies on the compound may unlock some of the mysteries of the age old disease, parkinsonism.
AuthorsS K Kulkarni, A K Mehta, K O Aley, V K Shukla
JournalMethods and findings in experimental and clinical pharmacology (Methods Find Exp Clin Pharmacol) Vol. 8 Issue 8 Pg. 485-9 (Aug 1986) ISSN: 0379-0355 [Print] SPAIN
PMID3489146 (Publication Type: Journal Article)
Chemical References
  • Monoamine Oxidase Inhibitors
  • Pyridines
  • Receptors, Dopamine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Humans
  • Monoamine Oxidase Inhibitors (pharmacology)
  • Parkinson Disease, Secondary (chemically induced)
  • Pyridines (metabolism, pharmacology)
  • Receptors, Dopamine (drug effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password:
Type Validation Code Shown: